Introduction {#Sec1}
============

The prevalence of dry eye syndrome worldwide ranges from 5% to 34% of the population \[[@CR15]\], and in the US is estimated to affect over 4% of men and almost 8% of women 50 years of age or older \[[@CR21], [@CR22]\]. Dry eye syndrome, which increases with age, is a multifactorial disease of the tears and ocular surface; symptoms include discomfort, visual disturbance, and tear film instability, with the potential for exposure of and damage to the ocular surface \[[@CR7]\]. Dry eye is accompanied by increased osmolarity of the tear film, which can lead to morphological changes in the cornea and conjunctiva. Dry eye also involves inflammation of the ocular surface, which can result in apoptotic cell death in the corneal epithelium \[[@CR3], [@CR37]\]. Current therapies for dry eye are only palliative, focusing on replacement of tears to reduce symptoms. Thus, there is a need for drugs that directly address the causes of dry eye.

Oxidative mechanisms are believed to play an important role in the pathogenesis of dry eye syndrome. SkQ1 is a novel small molecule developed to reduce oxidative stress in cell mitochondria, targeting and neutralizing mitochondrial reactive oxygen species (ROS). Mitochondria are one of the main sources of molecular oxygen consumption in the body \[[@CR12], [@CR29]\]. Natural antioxidants are not capable of penetrating mitochondria and neutralizing the excessive amounts of free radicals generated by these organelles. After ROS-dependent oxidation in the mitochondria, SkQ1 is reduced by the respiratory chain, making it a renewable active compound \[[@CR26]\]. The localization of SkQ1 in mitochondria and its ability to regenerate make it a potentially effective pharmacological agent for treating pathologies of the eye associated with oxidative stress and lipid and protein peroxidation in the inner membrane of the mitochondria, and for the prevention of the onset or progression of dry eye syndrome.

As a topical ophthalmic formulation for dry eye, SkQ1 has demonstrated statistically significant positive results in a Phase 2 clinical trial in the US for reduction of both signs and symptoms in subjects with mild to moderate dry eye syndrome, as discussed in this article. This study confirmed the results of a prior SkQ1 clinical study conducted in Russia and Ukraine \[[@CR5]\]. An ophthalmic formulation of SkQ1, Visomitin, was approved in Russia in December 2011 and has since been marketed there as a prescription product. Russian studies with SkQ1 have involved 633 subjects; the US Phase 2 study enrolled 91 subjects.

Materials and Methods {#Sec2}
=====================

The Phase 2 US study was a randomized, double-masked, placebo-controlled, single-center, 29-day clinical trial. The study evaluated the safety and efficacy of SkQ1 ophthalmic solution in the environment and during challenge in the Controlled Adverse Environment (CAE^SM^) chamber (Ora, Inc., Andover, MA, USA). The CAE is a clinical model used in the investigation of therapeutic agents to exacerbate the signs and symptoms of dry eye in a controlled manner by regulating humidity, temperature, airflow, lighting, and visual tasking within the CAE chamber. The CAE allows for standardized measurements of dry eye signs and symptoms and reduces variability \[[@CR18]\]. The study included several dry eye sign and symptom parameters, described below.

Study Population {#Sec3}
----------------

The subject selection process ensured that no subjects with underlying factors that could affect the conduct of the study or compromise subject safety enrolled in the study. All 91 subjects enrolled had clinical signs of mild to moderate dry eye for at least 6 months prior to study entry. The mean age of subjects was 62 years \[standard deviation (SD) 10.68\]; 24 subjects were men and 67 were women. Key inclusion criteria at Visits 1 and 2 included a corneal fluorescein staining score of ≥2 in at least one region pre-CAE, a total lissamine green conjunctival score of ≥2 pre-CAE, a Schirmer's test score of ≤10 and ≥1 mm, a score of ≥2 in at least one symptom pre-CAE, and a demonstrated response to the CAE, based on Ora Calibra™ scales (Ora, Inc., Andover, MA, USA) as discussed in this article.

All subjects had to have demonstrated a reproducible dry eye response to the CAE at Visits 1 and 2. Exclusion criteria included no recent history of ocular surgery/procedures, no clinically significant (CS) slit lamp findings, no ongoing ocular infection or inflammation, no Restasis^®^ (Allergan, Inc., Irvine, CA, USA) use within 30 days of Visit 1 (Day −7), no punctal plug use that was not stable within 30 days of Visit 1, no contact lens use within 7 days of Visit 1, and no use of medications known to cause ocular drying within 30 days of Visit 1.

Study Design {#Sec4}
------------

All subjects who met the inclusion and exclusion criteria were randomized 1:1:1 into one of three ophthalmic solution treatment groups, at SkQ1 1.55 µg/mL, SkQ1 0.155 µg/mL, or SkQ1 0.0 µg/mL (placebo). The placebo consisted of benzalkonium chloride, hypromellose, sodium chloride, sodium dihydrogen phosphate dihydrate, and sodium dihydrogen phosphate dodecahydrate, and was identical to the SkQ1 treatment drug formulation except that the active ingredient SkQ1 was absent. Subjects self-administered one to two drops twice daily (BID) for 29 days in the morning and evening, including self-administration at two in-office visits, as described below. Subjects also recorded dry eye symptoms in a diary. Investigator assessments occurred at all study visits.

The study involved 4 visits over approximately 5 weeks. Visit 1 (Day −7) was the screening visit; subjects were assessed for eligibility, including response to a 90-min CAE exposure. The study included a 1-week placebo (SkQ1 vehicle) run-in period between Visit 1 and Visit 2 for subject selection prior to randomization. At Visit 2 (Day 1), baseline efficacy and safety measures were taken and baseline values established; subjects received a 90-min CAE exposure and their responses to the CAE were confirmed. Also at Visit 2, subjects were then randomized into the three treatment groups and self-administrated the assigned study drug. Subjects continued to self-administer the study drug BID for 4 weeks. Visit 3 (Day 15) was the 2-week follow-up visit with efficacy and safety measures taken, and included subject self-administration of the study drug; no CAE exposure occurred at Visit 3. At Visit 4 (Day 29), the final 90-min CAE exposure occurred, efficacy and safety assessment measures were taken, and subjects exited the study.

Most efficacy measures for dry eye signs (corneal fluorescein staining, lissamine green staining, ocular protection index, blink rate, tear film break-up time (TFBUT), conjunctival redness, and lid margin redness) were assessed at each study visit (both pre- and post-CAE at Visits 1, 2, and 4, and once at Visit 3 at which no CAE exposure occurred). Additional measures for dry eye signs included corneal sensitivity, which was assessed at all study visits pre-CAE only, and Schirmer's test, which was conducted at all study visits post-CAE only.

Efficacy measures for dry eye symptoms included subject assessments of five symptoms (ocular discomfort, burning, dryness, grittiness, and stinging) assessed at all study visits (both pre- and post-CAE and at Visit 3); drop comfort assessed post-CAE at Visit 2 and Visit 3; and an ocular surface disease index (OSDI) questionnaire assessed pre-CAE at all visits.

Safety assessments for adverse events (AEs), visual acuity, and slit lamp biomicroscopy testing were conducted at all study visits; intraocular pressure (IOP), dilated fundoscopy, and pregnancy testing were conducted at Visits 1 and 4.

Statistical Analysis {#Sec5}
--------------------

SAS^®^ software Version 9.2 (SAS Institute, Middleton, MA, USA) was used for statistical analyses. Efficacy parameters were assessed at all study visits at all or some of the following time points: Visit 4 (Day 29)---Pre-CAE, Pre-CAE change from Baseline (Visit 2, Day 1), post-CAE, change from Visit 2 post-CAE, and change from pre- and post-CAE at Visit 4; and Visit 3 (Day 15) and Visit 3 change from Baseline. The unit of analysis for most efficacy endpoints was the worst eye of each subject, defined as the eye with the worse inferior corneal staining before CAE exposure at baseline (Visit 2, Day 1), or if inferior corneal staining was the same in both eyes, then the eye with the earliest onset of symptom reaction to the CAE at baseline. For other endpoints, the unit of analysis was the subject.

Two-sided two-sample *t* tests were calculated for levels of significance. A level of statistical significance of 0.05 was used for differences between the SkQ1 treatments and placebo. Wilcoxon rank sum tests were used to compare each dose of SkQ1 ophthalmic solution and placebo and for count or rank-based data, including symptom scores at individual time points. Analysis of covariance models were used to include baseline values as covariates where appropriate. Mixed-effect models were used to analyze individual dry eye symptoms from the subject diary.

The primary and secondary efficacy analyses were performed on the intent-to-treat (ITT) population, which included all randomized subjects. Sensitivity analysis was performed on the per-protocol population, which excluded subjects with significant protocol deviations or who did not complete the study. Safety assessments were performed on the safety population, which included all subjects who received treatment from whom at least one safety measurement was obtained following the first dose of study drug.

Study Procedures {#Sec6}
----------------

### Efficacy Measures {#Sec7}

The procedures used to assess efficacy measures are described below.

### Dry Eye Signs {#Sec8}

#### Corneal Fluorescein Staining {#Sec9}

Fluorescein staining of the cornea, commonly used to assess ocular surface damage, was assessed by the investigator using a slit lamp 3--5 min after instillation of 5 µL of 2% preservative-free sodium fluorescein solution into the inferior conjunctival cul-de-sac of each eye. A Wratten \#12 yellow filter was used to enhance the ability to grade fluorescein staining. Staining was assessed in precisely defined regions (inferior, superior, central, temporal, and nasal) of the ocular surface using the Ora Calibra™ Corneal and Conjunctival Staining Scale and the National Eye Institute (NEI)/Industry Workshop Scale (NEI scale) \[[@CR13]\]. The Ora Calibra 5-point scale ranges from 0 to 4 points (0 = none to 4 = confluent) \[[@CR23]\]. The 4-point NEI scale ranges from 0 = no staining present to 3 = severe staining.

#### Lissamine Green Staining {#Sec10}

Lissamine green staining, another measure of ocular surface damage, was assessed by the investigator using a slit lamp approximately 30 s after instillation of 10 µL of lissamine green solution into the inferior conjunctival cul-de-sac. The Ora Calibra Corneal and Conjunctival Staining Scale and the NEI scale (both scales described above) were used for assessment. The NEI grid divides the conjunctiva into six regions: far temporal, temporal-superior, temporal-inferior, nasal-superior, nasal-inferior, and far nasal; the intensity of staining in these regions was scored by the investigator using the NEI 0--3 scoring system.

#### Ocular Protection Index (OPI 2.0) {#Sec11}

An automated methodology was used to simultaneously measure TFBUT (described below) and Inter Blink Interval (IBI, the average time between blinks), as well as the area of tear film break up (percent of cornea exposed). Mean breakup area divided by IBI provides the OPI 2.0 score, reflecting a percentage of the area of tear film break up. Following instillation of fluorescein solution into the inferior conjunctival cul-de-sac, subjects' tear films were recorded using a camera system for one minute while the subjects watched television. A 15 frame-per-second video of the fluorescent eye under visual task was taken and a computer program analyzed the area of cornea with broken tear film on a frame-by-frame basis. IBI and OPI were calculated and produced as assessments of the level of drying of the ocular surface.

#### Blink Rate {#Sec12}

Blinks per minute were measured over a three-minute period, with a lower blink rate after treatment and CAE exposure associated with improvements in dry eye. A subject's blink rate (blinks per minute) was non-invasively assessed using automated controls and measured over a period of up to 10 min using a digital micro-camera system. The camera tracked the position of the upper eyelid over time and counted the number of times the upper eyelid moved out of its resting position. The blink rate was taken while the subject focused on a visual task. The camera was mounted onto a headset that fit any subject and used ambient illumination.

#### TFBUT {#Sec13}

The TFBUT test was performed in accordance with standard procedures. For each eye, two measurements were taken and averaged unless the two measurements were \>2 s apart and were each \<10 s, in which case, a third measurement was taken and the two closest of the three were averaged and used for analysis. If the difference between the two sequential pairs was the same (e.g., 3, 6, 9 s), then the median of the three readings was used for analysis. Less time indicated a faster break-up of the tear film, which in turn indicates an unstable tear film characteristic of evaporative dry eye.

#### Corneal Sensitivity {#Sec14}

Corneal sensitivity was measured with a Cochet--Bonnet aesthesiometer, using vertical nylon threads of different lengths (mm) that touch the corneal surface. A lower value indicates less corneal sensitivity. The length at which the subject reported stimulus was recorded as the corneal sensitivity.

#### Unanesthetized Schirmer's Test {#Sec15}

A sterile Schirmer's strip was placed in the lower temporal lid margin for 5 min, at which point the length of moistened strip was recorded as an indication of tear production. A normal Schirmer's test results in ≥15 mm wetting of the paper after 5 min; lower values indicate more severe lack of tear production (a sign of dry eye syndrome).

#### Conjunctival Redness {#Sec16}

Conjunctival redness was assessed by the investigator using the 5-point (0--4) Ora Calibra Conjunctival Redness Scale (0 = none, and 4 = most severe).

#### Lid Margin Redness {#Sec17}

Lid margin redness was assessed by the investigator using the Ora Calibra 4-point (0--3) Lid Margin Redness Scale (0 = none, and 3 = most severe).

### Dry Eye Symptoms {#Sec18}

#### Ocular Discomfort {#Sec19}

Ocular discomfort scores were subjectively graded by the subjects according to the 5-point Ora Calibra Ocular Discomfort Scale (0--4, with 0 = no discomfort and 4 = constant discomfort) \[[@CR23]\]. Each eye was rated separately. Subjects assessed ocular discomfort at time 0 and every 5 min thereafter during the 90-min CAE exposures. Subjects also assessed ocular discomfort at Visits 1, 2, and 4, before and after the CAE exposure, and also at Visit 3 when no CAE exposure occurred.

#### Dry Eye Symptoms and Ocular Discomfort {#Sec20}

Other dry eye symptoms as well as ocular discomfort were assessed for both eyes of each subject at all scheduled visits, pre-CAE and post-CAE at Visits 1, 2, and 4 and once at Visit 3 (Day 15) when no CAE was performed. The symptoms assessed by subjects were: overall ocular discomfort, burning, dryness, grittiness, and stinging, according to the 6-point (0--5) Ora Calibra™ Ocular Discomfort and 4-Symptom Questionnaire, in which 0 = none and 5 = most.

#### Drop Comfort {#Sec21}

Drop comfort was assessed for each eye by the subject immediately following initial dosing with the study drug and at 1 and 2 min following dosing using the Ora Calibra Drop Comfort Scale, where 0 = very comfortable and 10 = very uncomfortable. Subjects also assessed drop comfort at 3 min following initial dosing using the Ora Calibra Drop Comfort Questionnaire by choosing 3 descriptor words from a list of 12 words (i.e., burning, cool, sticky) or inserting their own descriptor as part of the questionnaire.

#### Ocular Surface Disease {#Sec22}

An OSDI Questionnaire was used to evaluate the impact of a subject's dry eye disease on vision-related functioning. A negative change from baseline indicated an improvement in vision-related functioning. Study staff asked the subject a series of 12 questions related to the frequency of occurrence of dry eye symptoms over the previous week. Subjects rated each eye using a 5-point scale where 0 = none of the time and 4 = all of the time.

Safety Measures {#Sec23}
---------------

The procedures used to assess safety measures are described below.

### AEs {#Sec24}

All AEs regardless of relationship to the test article were monitored, reported, and recorded throughout the study.

### Visual Acuity {#Sec25}

Best corrected visual acuity was assessed for both eyes at all study visits (pre-CAE at visits in which CAE occurred) using an ETDRS chart. Study staff indicated on the case report form whether VA was measured with or without correction and if pin-hole was used. Number of letters read correctly was converted to logarithm of the minimum angle of resolution (logMAR) scores.

### Slit Lamp Biomicroscopy {#Sec26}

Slit lamp biomicroscopy examinations were conducted on both eyes at all study visits (pre-CAE and post-CAE at visits in which CAE occurred). The slit lamp findings included examinations of cornea, conjunctiva, anterior chamber, iris, lens, and lid. Each parameter was graded as normal or abnormal. Abnormal findings were further classified as CS or not CS (NCS).

### Dilated Fundoscopy {#Sec27}

Dilated fundoscopy examinations were conducted on both eyes at Visit 1 (Day −7) and Visit 4 (Day 29) post-CAE. The fundus pathology findings included examinations of the vitreous, retina, macula, choroid, and optic nerve, and were recorded as normal, abnormal non-clinically significant (NCS), or abnormal clinically significant (CS).

### IOP {#Sec28}

IOP was measured by contact tonometry on both eyes at Visits 1 and 4 (post-CAE).

Dose Selection {#Sec29}
--------------

In a scopolamine and dry eye CAE mouse model study (70 mice) with SkQ1 ophthalmic solution 0.155 μg/mL as topical treatment (3 μL) on days 1--12, SkQ1 statistically significantly reduced corneal staining for the once daily (QD) and BID doses compared to vehicle alone, with QD administration scores lower than vehicle at Day 4 (*p* \< 0.01), and BID administration lower than vehicle at days 4 (*p* \< 0.01) and 12 (*p* \< 0.05). These results suggested that SkQ1 ophthalmic solution 0.155 μg/mL had a rapid onset of action as well as a long duration of action, that BID dosing was optimal, and that clinical testing of SkQ1 as a dry eye treatment was warranted \[[@CR35]\].

Animal study data on SkQ1 lead to the selection of two test concentrations in the Phase 2 US study: the 0.155 μg/mL concentration used in preclinical studies, and a higher 1.55 μg/mL concentration. In a local tolerance study (acute eye irritation in rabbits), a single dose of 155 ng/mL (0.015 μg/eye) showed no ocular irritation. A repeat dose study (28-day ocular toxicity with 14-day recovery period in rabbits) tested three concentrations of the SkQ1 ophthalmic solution and demonstrated that 0.15 μg/eye three times daily (TID) (0.45 μg/eye/day) showed no ocular irritation; 1.5 μg/mL TID (4.5 μg/eye/day) showed no-observed-adverse-effect-level (NOAEL) for ocular toxicity; and 15 μg/eye TID (45 μg/eye/day) showed mild ocular irritation/NOAEL for systemic toxicity.

With a 0.1-mL dose at the highest concentration (0.1 mL × 1.55 μg/mL BID = 0.31 μg/eye/day), the amount of SkQ1 instilled falls within a safety margin of 10 for systemic exposure observed at the NOAEL for ocular toxicity, 4.5 μg/eye/day. The lower concentration (0.1 mL × 0.155 μg/mL BID = 0.031 μg/eye/day) falls well within the same safety margin. Data indicated that SkQ1 ophthalmic solution (0.155 and 1.55 μg/mL) could be expected to be safe and well tolerated in monitored human subjects studied at these concentrations (1.55 μg/mL BID = 3.1 μg/eye/day and 0.155 μg/mL BID = 0.31 μg/eye/day). Thus, the preclinical studies supported dosing at the higher concentration of 1.55 μg SkQ1/mL, with no evidence of systemic exposure at either 1.55 μg/mL or 0.155 μg/mL with BID dosing.

Compliance with Ethics Guidelines {#Sec30}
---------------------------------

The study was Institutional review board-approved (Alpha IRB) and registered (Clinicaltrials.gov identifier: NCT02121301).

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013. Informed consent was obtained from all patients at the beginning of the study.

Results {#Sec31}
=======

Of the 91 randomized subjects, 87 subjects completed the study, and four discontinued, one for a protocol deviation and 3 by subject choice.

Results for several efficacy measures in this Phase 2 study indicated that SkQ1 was efficacious in treating dry eye signs and symptoms, even though findings did not meet the primary efficacy endpoints for this study of statistically significant treatment differences between SkQ1 and placebo in mean score pre-CAE for corneal fluorescein staining in the inferior region at Visit 4 (Day 29), and in mean score for worst dry eye symptom over the 7 days preceding Visit 4.

For dry eye signs, statistically significant results demonstrating SkQ1 efficacy occurred for corneal fluorescein staining, lissamine green conjunctival staining, and lid margin redness. For dry eye symptoms, statistically significant results occurred that indicated less ocular discomfort, dryness, and grittiness for SkQ1-treated subjects compared to subjects treated with placebo. Additional dry eye sign measurements, although not statistically significant, also indicated superior SkQ1 efficacy compared to placebo, and included corneal fluorescein staining for all other corneal regions at some time points, lissamine green staining for the central and nasal conjunctival regions, and blink rate.

Regarding safety, both doses of SkQ1 were safe. No serious AEs occurred, rates of AEs were similar between the SkQ1 treatment groups and the placebo group, and no subjects discontinued the study because of AEs. No CS safety issues were identified. Subjects reported good comfort and tolerability with SkQ1.

Results for each of the efficacy and safety parameters are discussed below.

Corneal Fluorescein Staining {#Sec32}
----------------------------

As shown in Table [1](#Tab1){ref-type="table"}, both concentrations of SkQ1 decreased corneal fluorescein staining more than placebo treatment at Visit 4 (Day 29) for change from pre- to post-CAE in 7 of 8 corneal regions and for post-CAE in 3 of 8 regions (5 of 8 regions for 1.55 µg/mL SkQ1), indicating a reduction (improvement) in this dry eye sign. Using the Ora Calibra scale, 1.55 µg/mL SkQ1 was statistically significantly more effective than placebo (*p* = 0.0215) in reducing central corneal fluorescein staining at Visit 4 (Day 29) for mean change from pre- to post-CAE.Table 1Corneal fluorescein staining scores post-CAE^SM^Time pointEndpoint (region)^a^Mean (SD) (*p* value)^b^1.55 µg/mL (*N* = 30)0.155 µg/mL (*N* = 30)Placebo (*N* = 31)Visit 4\
Post-CAE (Day 29)Total score10.92 (2.918)11.12 (2.912)10.85 (3.217)Corneal sum6.80 (2.136)6.98 (1.882)6.68 (2.246)Conjunctival sum**4.12 (1.092)** ^**c**^\
**(** ***p*** **=** **0.8871)4.13 (1.438)**\
**(** ***p*** **=** **0.9252)**4.17 (1.295)Inferior**2.86 (0.896)**\
**(** ***p*** **=** **0.8695)**2.97 (0.880)2.90 (0.894)Superior2.44 (0.754)2.52 (0.701)2.25 (0.751)Central**1.50 (0.979)**\
**(** ***p*** **=** **0.9020)1.50 (0.861)**\
**(** ***p*** **=** **0.8909)**1.53 (1.008)Temporal**1.94 (0.618)**\
***(p*** **=** **0.8794)**1.97 (0.718)1.97 (0.669)Nasal**2.18 (0.593)**\
**(** ***p*** **=** **0.9143)2.17 (0.781)**\
**(** ***p*** **=** **0.8666)**2.20 (0.750)Visit 4\
Change from Visit 2 post-CAETotal score**−0.70 (2.160)−**1.23 (2.690)**−**0.95 (2.578)Corneal sum**−**0.32 (1.513)**−0.82 (1.709)**\
**(** ***p*** **=** **0.7599)−**0.68 (1.653)Conjunctival sum**−**0.38 (1.348)**−**0.42 (1.352)**−**0.27 (1.172)Inferior**−0.20 (0.707)**\
**(** ***p*** **=** **0.7906)−**0.27 (0.716)**−**0.25 (0.679)Superior**−**0.02 (0.530)**−**0.20 (0.826)**−**0.27 (0.751)Central**−**0.10 (0.816)**−**0.35 (0.658)**−**0.17 (0.699)Temporal**−**0.12 (0.794)**−**0.18 (0.725)**−**0.07 (0.691)Nasal**−**0.26 (0.818)**−**0.23 (0.785)**−**0.20 (0.690)Visit 4\
Change from pre- to post- CAE (Day 29)Total score**1.36 (2.452)**\
**(** ***p*** **=** **0.2643)1.05 (2.131)**\
**(** ***p*** **=** **0.0904)**2.20 (2.973)Corneal sum**1.06 (1.764)**\
**(** ***p*** **=** **0.2844)0.90 (1.694)**\
**(** ***p*** **=** **0.1425)**1.63 (2.105)Conjunctival sum**0.30 (1.099)**\
**(** ***p*** **=** **0.3881)0.15 (0.882)**\
**(** ***p*** **=** **0.1223)**0.57 (1.158)Inferior0.80 (0.901)**0.57 (0.666)**\
**(** ***p*** **=** **0.3023)**0.78 (0.926)Superior**0.34 (0.703)**\
**(** ***p*** **=** **0.9639)0.23 (0.817)**\
**(** ***p*** **=** **0.5994)**0.35 (0.892)Central**−0.08 (0.965)**\
**(** ***p*** **=** **0.0215)0.10 (0.845)**\
**(** ***p*** **=** **0.0728)**0.50 (0.851)Temporal**0.12 (0.711)**\
**(** ***p*** **=** **0.4184)0.03 (0.507)**\
**(** ***p*** **=** **0.1402)**0.28 (0.762)Nasal**0.18 (0.497)**\
**(** ***p*** **=** **0.4874)0.12 (0.568)**\
**(** ***p*** **=** **0.2663)**0.28 (0.583)*CAE* controlled adverse environment, *SD* standard deviation^a^Scales: Each region is assessed on a 0--4 scale with a '4' indicating the most staining; half (0.5) units may be usedCorneal sum: sum of the inferior, superior, and central regions resulting in a corneal sum reported on a 0--12 scaleConjunctival sum: sum of the temporal and nasal regions resulting in a conjunctival sum reported on a 0--8 scaleTotal sum: sum of all five regions: inferior, superior, central, temporal, and nasal, resulting in a total sum reported on a 0--20 scale^b^2-sided *p* value calculated using a two-sample *t* test^c^Results indicating numerical superiority of SkQ1 over placebo and associated *p* values are shown in bold type. CAE was not conducted at Visit 3

Using the NEI scale, mean central fluorescein staining scores for this same time point indicated statistical significance for the 1.55 µg/mL SkQ1 (*p* = 0.0291) for reduction of central corneal staining. In addition, for several other corneal regions/scores, SkQ1 0.155 µg/mL demonstrated superior efficacy compared to placebo, although the differences were not statistically significant, including total staining, the central region, and the corneal sum score (sum of scores from the inferior, superior, and central regions) (Visit 4 change from pre- to post-CAE); and the temporal region (Visit 3 change from baseline).

Figure [1](#Fig1){ref-type="fig"} shows the differences in central corneal fluorescein staining scores in the ITT population comparing pre- and post-CAE at Day 1, and Fig. [2](#Fig2){ref-type="fig"} shows the same parameters at Day 29.Fig. 1Differences in central corneal fluorescein staining scores in the ITT population when compared pre- and post-CAE^SM^ at Day 1. Lower corneal staining scores indicate less dry eye. *CAE* controlled adverse environment, *ITT* intent-to-treatFig. 2Differences in central corneal fluorescein staining scores in the ITT population when compared pre- and post-CAE^SM^ at Day 29. Lower corneal staining scores indicate less dry eye. The SkQ1 1.55 µg/mL dose had statistically significant reduction in central corneal fluorescein staining compared to placebo. There was a trend towards statistically significant lower staining for the SkQ1 0.155 µg/mL dose compared to placebo. *CAE* controlled adverse environment, *ITT* intent-to-treat

Lissamine Green Staining {#Sec33}
------------------------

Using the Ora Calibra scale, the 0.155 µg/mL SkQ1 concentration was statistically significantly more effective than placebo (*p* = 0.0458) in reducing lissamine green staining for the central region at Visit 4 mean change from pre- to post-CAE, with scores of −0.12 (SD 0.313) for the 0.155 SkQ1 group and 0.00 (SD 0.000) for the placebo group (lower scores reflect less dry eye). In addition, for other time points, SkQ1 demonstrated superior efficacy compared to placebo in reducing lissamine green staining, although the differences were not statistically significant, including the central region (Visit 4 change from pre-CAE baseline, 1.55 µg/mL SkQ1) and nasal region (Visit 4 change from post-CAE baseline, both SkQ1 concentrations).

Lid Margin Redness {#Sec34}
------------------

There were statistically significant improvements (decreases) in lid margin redness scores at several time points for both SkQ1 concentrations compared to placebo. This occurred for the 1.55 µg/mL SkQ1 concentration at Visit 4 for: post-CAE (*p* = 0.0039), post-CAE change from Visit 2 post-CAE baseline (*p* = 0.0098), and pre- to post-CAE (*p* = 0.0224). Statistically significant efficacy also occurred for the 0.155 µg/mL SkQ1 concentration compared to placebo at Visit 4 for pre-CAE (*p* = 0.0319), post-CAE (*p* = 0.0028), and post-CAE change from Visit 2 post-CAE baseline (*p* = 0.0451). At Visit 3, SkQ1 0.155 µg/mL showed greater efficacy in reducing lid margin redness compared to placebo, although the differences were not statistically significant.

OPI {#Sec35}
---

There were no statistically significant differences in OPI values between either of the SkQ1 concentrations and placebo at Visits 3 and 4.

Blink Rate {#Sec36}
----------

Blink rate scores for the 1.55 µg/mL SkQ1 concentration demonstrated greater SkQ1 efficacy (i.e., a decrease in scores) compared to placebo at Visit 4 for change from Visit 2 post-CAE baseline, and at Visit 4 change from pre- to post-CAE. There were no important differences in blink rate between the 0.155 µg/mL SkQ1 concentration and placebo throughout the study.

The remaining efficacy measures for signs of dry eye (TFBUT, conjunctival redness, corneal sensitivity, and Schirmer's test) either did not show statistically significant differences between the SkQ1 groups and the placebo group or showed significance for the placebo.

Dry Eye Symptoms {#Sec37}
----------------

Table [2](#Tab2){ref-type="table"} reflects the results of several dry eye symptom analyses. Dry eye symptom scores for ocular discomfort for SkQ1 (using the Ora Calibra Ocular Discomfort and 4-Symptom Questionnaire) showed statistically significant improvement for SkQ1 0.155 µg/mL relative to placebo (*p* = 0.0137) at Visit 4 (Day 29, change from pre- to post-CAE) in an ad hoc analysis subtracting pre- to post-CAE change at Visit 2. This analysis was performed because in some analyses, differences were observed among the treatment groups at Visit 2 post-CAE, suggesting a baseline imbalance in the chamber. (The first dose of assigned study medication was instilled after all assessments at Visit 2 post-CAE.) Figure [3](#Fig3){ref-type="fig"} shows the differences in ocular discomfort scores at Visit 4 (Day 29) compared to Baseline (Visit 2) in this analysis.Table 2Results for several dry eye symptom analysesParameter/time point1.55 µg/mL SkQ1 (*N* = 30)0.155 µg/mL SkQ1 (*N* = 30)Placebo (*N* = 31) *Initial (planned) analysis* Worst dry eye symptom^a^Mean (SD)^b^  Average (days 22--28)2.52 (0.899)2.54 (0.993)2.39 (1.063)  Change from baseline−0.46 (0.122)−0.31 (0.116)−0.52 (0.116) Grittiness  V2 (Day 1, baseline)   Post-CAE^c^2.6 (1.77)2.3 (1.84)2.3 (1.41)   Change from pre- to post-CAE0.6 (1.00)0.6 (1.19)0.5 (1.36)  V4 (Day 29)   Post-CAE2.4 (1.70)**1.8 (1.78)** ^**d**^\
**(** ***p*** **=** **0.2525)**2.3 (1.56)   Post-CAE change from baseline**−0.5 (0.90)**\
**(** ***p*** **=** **0.1094)−0.4 (1.10)**\
**(** ***p*** **=** **0.1463)**0.0 (1.17)   Change from pre- to post-CAE**0.6 (0.90)**\
**(** ***p*** **=** **0.7452)0.3 (1.08)**\
**(** ***p*** **=** **0.1160)**0.7 (1.02)*Ad hoc analyses* Analysis subtracting pre- to post-CAE change at V2^e^  Ocular discomfort   V4 (Day 29)    Change from pre- to post-CAE1.4 (1.03)1.2 (1.25)1.2 (0.94)    Change from pre- to post-CAE (with V2 pre- to post-CAE subtracted)**0.1 (1.21)**\
**(** ***p*** **=** **0.3038)−0.3 (1.12)**\
**(** ***p*** **=** **0.0137)**0.5 (1.31)DrynessGrittinessDrynessGrittinessDrynessGrittiness*Ad hoc analyses* Analysis with subjects categorized by baseline corneal fluorescein staining \[CFS\] scores)^f^  Low baseline inferior CFS group   V2 (Day 1, baseline) change from pre- to post-CAE1.1 (1.06)0.5 (0.97)1.3 (1.25)1.3 (0.76)0.8 (0.62)0.3 (0.89)V4 (Day 29)    Change from pre- to post-CAE1.7 (0.88)0.6 (0.91)1.4 (0.98)1.0 (0.58)0.9 (1.31)0.3 (0.45)    Change from pre- to post-CAE (with V2 pre- to post-CAE subtracted)0.7 (0.98)0.1 (0.96)**0.0 (0.90)**\
**(** ***p*** **=** **0.9642)−0.3 (0.76)**\
**(** ***p*** **=** **0.6698)**0.2 (1.19)−0.1 (1.08)  High baseline inferior CFS group   V2 (Day 1, baseline) change from pre- to post-CAE1.1 (0.98)0.8 (1.07)1.2 (0.86)**0.4 (1.24)**\
**(** ***p*** **=** **0.6561)**0.6 (0.86)0.6 (1.61)   V4 (Day 29)    Change from pre- to post-CAE1.6 (0.95)**0.7 (0.95)**\
**(** ***p*** **=** **0.4997)1.2 (1.24)**\
**(** ***p*** **=** **0.5903)0.0 (1.11)**\
**(** ***p*** **=** **0.0113)**1.4 (1.18)1.0 (1.19)    Change from pre- to post-CAE (with V2 pre- to post-CAE subtracted)**0.4 (1.14)**\
**(** ***p*** **=** **0.2702)−0.4 (0.97)**\
**(** ***p*** **=** **0.2621)0.0 (1.20)**\
**(** ***p*** **=** **0.0229)−0.4 (0.94)**\
**(** ***p*** **=** **0.1148)**0.8 (1.18)0.3 (1.88)*SD* standard deviation, *V* visit, *CAE* controlled adverse environment, *CFS* corneal fluorescein staining^a^Worst dry eye symptom (ocular discomfort, dryness, or grittiness) over the 7 days preceding Visit 4 (days 22--28; determined from symptom scores during the 1-week run-in period between Visits 1 and 2)^b^Grading scale ranges from 0 to 5, with 0 = no symptom and 5 = worst symptom^c^CAE was performed at Visits 1, 2, and 4. CAE was not performed at Visit 3^d^Results indicating numerical superiority of SkQ1 over placebo and associated *p* values are shown in bold type. *p* values = 2-sided two-sample *t* test^e^An ad hoc analysis subtracting pre- to post-CAE change at Visit 2 was conducted because in some analyses, differences were observed among the treatment groups at Visit 2 post-CAE, suggesting a baseline imbalance in the chamber. (The first dose of assigned study medication was instilled after all assessments at Visit 2 post-CAE.)^f^An ad hoc subgroup analysis was conducted, with subjects categorized into two subgroups based on their baseline corneal fluorescein staining scores (low or high baseline fluorescein staining groups)Fig. 3Ocular discomfort scores for SkQ1compared to placebo. Lower ocular discomfort scores indicate less discomfort. Ocular discomfort in the ITT population at Visit 4 (Day 29) pre- to post-CAE^SM^ (with Visit 2 baseline change from pre- to post-CAE subtracted) was statistically significantly reduced in the SkQ1 0.155 µg/mL treatment group compared to the placebo group. Ocular discomfort was also notably lower in the SkQ1 1.55 µg/mL treatment group compared to placebo. *CAE* controlled adverse environment, *ITT* intent-to-treat

When subjects were categorized into subgroups according to their baseline corneal fluorescein staining scores (Visit 2, pre-CAE), dryness was statistically significantly lower (*p* = 0.0229) in the SkQ1 0.155 µg/mL high-baseline subgroup compared to the placebo group. Generally, the treatment effect of SkQ1 on symptoms was enhanced when evaluating subjects with higher baseline levels of staining.

In addition, in the general, planned analysis, grittiness scores at Visit 4 for change from baseline post-CAE and change from pre- to post-CAE demonstrated greater efficacy at both SkQ1 concentrations compared to placebo, and in the ad hoc subgroup analysis, at Visit 4 the grittiness score for change from pre- to post-CAE in the 0.155 µg/mL treatment group for subjects with High Baseline Inferior Corneal Staining was statistically significant (*p* = 0.0113) compared to placebo.

Using the Ora Calibra Drop Comfort Scale, no statistically significant treatment differences were found in comfort levels for either concentration of SkQ1 compared to placebo at any of the time points evaluated (Visit 2 and Visit 3). Subjects in all three treatment arms generally rated the drops as comfortable. Using the Ora Calibra Drop Comfort Questionnaire, the most commonly chosen adjectives for all three treatment groups were positive, and included cool, comfortable, soothing, and refreshing. In addition, using the OSDI, subject responses regarding poor vision indicated fewer dry eye symptoms with SkQ1 use compared to placebo (at Visit 4, and Visit 4 change from baseline).

Safety Results {#Sec38}
--------------

### AEs {#Sec39}

Both doses of SkQ1 ophthalmic solution (1.55 and 0.155 µg/mL) were safe and well tolerated as administered (BID) in this study and compared to placebo. No CS safety issues were identified with the use of SkQ1 ophthalmic solution at either concentration. Rates of ocular and non-ocular AEs were similar between the SkQ1 treatment groups and the placebo group. No serious AEs (SAEs) occurred, and no subjects were discontinued due to AEs. A total of 18 treatment-emergent AEs (TEAEs) occurred in this study: 7 TEAEs in the SkQ1 1.55 µg/mL group, 6 TEAEs in the SkQ1 0.155 µg/mL group, and 5 TEAEs in the placebo group; only three of these TEAEs were suspected of being related to treatment (2 TEAEs in the placebo group, and one TEAE in the SkQ1 0.155 µg/mL group), as shown in Table [3](#Tab3){ref-type="table"}.Table 3Relationship of TEAEs to treatmentClassification of TEAEs by possible relationship to treatmentReported TEAEs by treatment groupSkQ1 1.55 µg/mLSkQ1 0.155 µg/mLPlaceboOcular Suspected1 (ocular discomfort)2 (blurred vision) Not suspected11Non-ocular Suspected1 (headache) Not suspected651Total765*Suspected* TEAE was suspected of being related to the treatment, *not suspected* TEAE was suspected of not being related to the treatment, *TEAEs* treatment-emergent adverse events

No effects on visual acuity, IOP, slit lamp biomicroscopy tests, or dilated fundoscopy were observed. Any abnormal findings were reported at baseline and all were considered not CS. Regarding visual acuity, there were no CS differences in the group mean visual acuity (logMAR) scores between either of the SkQ1 treatment groups and the placebo group at any study visit. In addition, there were no CS differences noted among the treatment groups in the proportions of subjects with normal, abnormal (NCS), and abnormal (CS) slit lamp findings; the same was true for dilated fundoscopy findings. For IOP, there were no CS differences in mean IOP values or change in IOP between either concentration of SkQ1 and placebo at the two time points measured (Visit 1 and Visit 4).

Both concentrations of SkQ1 were demonstrated to be safe and well tolerated ophthalmic products for use in dry eye subjects.

Discussion {#Sec40}
==========

Oxidative Stress {#Sec41}
----------------

Oxidative stress is involved in a variety of diseases, including cancer, Alzheimer's disease, Parkinson's disease, and cardiovascular, lung, and skin diseases, as well as ocular conditions including macular degeneration, uveitis, cataracts, corneal and ocular surface inflammation, and dry eye \[[@CR6], [@CR33]\]. Oxidative stress occurs with excessive levels of ROS, a type of free radical produced as a byproduct of cellular mitochondrial respiration. At normal levels, ROS is important in cell signaling and homeostasis \[[@CR6]\]. ROS, oxidative stress, and inflammation are important factors in dry eye disease, for which inflammation is considered the primary mechanism \[[@CR31]\]. The relationship between oxidative stress and inflammation in dry eye disease continues to be explored. High levels of ROS and oxidative stress markers have been identified in the tear film and conjunctiva of Sjogren syndrome patients \[[@CR32]\], in superficial punctate keratopathy in corneal epithelia \[[@CR17]\], in the tear film of dry eye patients \[[@CR1]\], and in animal models of dry eye \[[@CR6]\].

Wakamatsu et al. \[[@CR33]\] discussed antioxidant enzyme activity in the eye, with the highest levels found in the retina, lower levels in the sclera and cornea, and tears containing little such enzymatic activity \[[@CR4]\]. Thus, except for the retina, the eye contains few protections against free radicals/ROS. It has been suggested that lactoferrin \[[@CR24]\] or selenium \[[@CR8]\] may provide protection of the corneal epithelium. SkQ1 belongs to a relatively new class of chemical compounds---mitochondria-targeted antioxidants---capable of targeting and neutralizing mitochondrial ROS \[[@CR10], [@CR27]\].

Aging, Environmental, and Lifestyle Contributors to Dry Eye Disease {#Sec42}
-------------------------------------------------------------------

Aging, which commonly results in decreased tear production and flow, and certain hormonal changes (e.g., during menopause) are major contributors to dry eye disease, with oxidative stress involved in the natural aging process \[[@CR33]\]. In addition, acute and chronic environmental conditions can contribute to oxidative stress in the ocular surface, resulting in dry eye. Environmental and lifestyle contributors to dry eye are numerous and include: exposure to low humidity outdoors or indoors; tobacco smoke; wind; sun \[ultraviolet (UV)\] exposure; pollutants; ozone; certain medications, such as antihistamines, antidepressants, and beta-blockers; certain medical conditions, including other ocular conditions (e.g., blepharitis, allergic conjunctivitis), rheumatoid arthritis, Sjogren's syndrome, or contact dermatitis; contact lens use; and activities that decrease blinking, such as prolonged computer use or reading. SKQ1 has been shown to play a key role in the treatment of age-related diseases \[[@CR11], [@CR16], [@CR28]\], slow age-dependent retinal degeneration \[[@CR19]\], and increase the resistance of the lens to UV-irradiation \[[@CR30]\].

Dry Eye Models {#Sec43}
--------------

Animal and human models of dry eye can reflect the environmental conditions that contribute to oxidative stress and dry eye. A rat model of dry eye using low-humidity airflow suggested a strong relationship between oxidative stress and corneal surface disorder \[[@CR17]\]. A mouse model reflecting age-related ocular changes in the retina indicated that oxidative stress may play a role in retinal degeneration, and that the superoxide dismutase (SOD) enzyme may protect retinal pigment epithelium from age-related degeneration \[[@CR9]\]. Using this same mouse model, another study found that SOD1 may also provide protection for the dry eye parameters of tear function, the ocular surface, and the lacrimal gland \[[@CR34]\].

SkQ1 or related molecules have been shown to be active in a variety of animal models of illness believed to involve free radical damage. These include rat models of H~2~O~2~ and ischemia-induced heart arrhythmia, heart infarction, kidney ischemia, and stroke, studied both ex vivo and in vivo \[[@CR2]\]. In addition, SkQ1 has shown efficacy in a number of eye disease models. Ocular preclinical studies with SkQ1 have included dry eye models in mice, and uveitis and retinal degeneration models in rats \[[@CR14], [@CR20], [@CR30]\]. In the Phase 2 US clinical trial, SkQ1 was investigated using the CAE model to reflect the oxidative stress conditions of dry eye. The post-CAE results of this study as reported here indicate that SkQ1 treatment prior to CAE exposure protects the ocular surface from oxidative stress and provides a novel approach to dry eye treatment.

Preclinical Studies with SkQ1 {#Sec44}
-----------------------------

Preclinical studies have shown that SKQ1 effectively modulates mitochondria membrane electric potential, reduces cellular destruction and damage caused by excessive concentrations of ROS, and decreases ocular surface inflammation \[[@CR25], [@CR38]\]. Based on a full range of animal toxicology studies, no adverse effects on general behavior or the central nervous system were observed (in rats orally administered SkQ1 at 0, 5, 25, or 100 mg/kg), or for cardiovascular parameters, pulse pressure, electrocardiography, body temperature, or clinical condition (in Beagle dogs orally administered SkQ1 at 0.00, 7.75, 77.5, or 775 μg/kg) (unpublished reports). A mouse model study showed the efficacy of SkQ1 for the reduction of corneal staining, as discussed in the "Dose Selection" section above.

Possible Study Limitations {#Sec45}
--------------------------

Limitations of some of the available diagnostic tools (e.g., Schirmer's test, corneal fluorescein staining) may contribute to mixed underlying etiologies. Use of several dry eye tests compensates somewhat for these test limitations. In addition, seasonality may contribute to a reduction in the effects of dry eye treatments as the drier season progresses. In addition, environmental factors, such as subjects' increased use of computers or reading or exposure to pollutants or certain medications, may also decrease the effects of dry eye treatments. Using a dry eye model (e.g., CAE chamber) that regulates humidity, temperature, airflow, lighting, and visual tasking, as used in the US Phase 2 study, can help control and minimize these potential confounding factors.

Prior SkQ1 Clinical Studies {#Sec46}
---------------------------

The Phase 2 US clinical trial followed two clinical studies conducted in Russia. The first Russian clinical trial of SkQ1 demonstrated efficacy in treating signs and symptoms of dry eye compared to an artificial tear treatment \[[@CR36]\], after which Visomitin SkQ1 ophthalmic solution was approved in Russia (December 2011) and has since been marketed there as a prescription product. The second Russian clinical study assessed the safety, tolerability, and efficacy of Visomitin compared with placebo (the same artificial tears formulation used in the initial Visomitin study) \[[@CR5]\]. The results of the second Russian study indicated that SkQ1 was safe and well tolerated by subjects, and restored corneal cell function and tear film stability, with improvements in both symptoms and corneal staining associated with dry eye. Post-therapy efficacy of Visomitin for TBUT, corneal staining, and symptoms over 6 weeks of a follow-up observation period showed a clear advantage of Visomitin over artificial tear treatments. The US Phase 2 clinical trial confirmed the safety and efficacy of SkQ1 dry eye treatment.

For future studies, categorizing subjects by both their worst dry eye symptom score and their corneal fluorescein staining scores may be useful in determining treatment efficacy, particularly when changes from pre-CAE and post-CAE scores at the end of the four-week treatment cycle are compared to baseline pre- to post-CAE scores.

Conclusions {#Sec47}
===========

This Phase 2 clinical trial indicated that SkQ1 is efficacious for the treatment of dry eye signs and symptoms and supported prior study results. SkQ1 was safe for use in the study's dry eye subjects, who found SkQ1 to be well tolerated and comfortable. Future studies will be conducted to confirm the efficacy and safety of SkQ1 ophthalmic solution.
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